ARCT-810 generally safe and well tolerated, demonstrating encouraging activity across key urea cycle biomarkers in ongoing ...
While artificial intelligence can help biotech and pharma companies more quickly vet job applicants, it can also turn off the ...
Tech darling Enveda has raised a total of $845 million in the past six years. The latest funding round is intended to pave ...
After imeroprubart failed to demonstrate sufficient efficacy in lupus during a Phase 2b trial, Immunovant is moving on from ...
In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A ...
Lyrfigtu demonstrated a confirmed ORR of 46% and mDOR of 11.8 months, with a predictable and manageable safety profile FORT ...
Biotechs that announced series B financing this year and are expanding their workforces include one that raised $2.1 billion and has partnerships with Eli Lilly, Johnson & Johnson and Novartis.
Once registered, participants may begin forwarding their questions for the CEO to Tribe Public at research@tribepublic.com or ...
Ulefnersen, an RNA-targeted therapy being developed by Ionis Pharmaceuticals and Otsuka Pharmaceutical, improved measurements ...
A late-stage test of Roche and Ionis Pharmaceuticals’ sefaxersen showed that the drug reduced protein in the urine, which ...
Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it is filing a ...
Amgen is awaiting another Phase 3 readout for the investigational Sjögren's disease therapy, set for later this year. William Blair anticipates that at least two trials will be needed to support an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results